Preparation, macrophages targeting delivery and anti-inflammatory study of pentapeptide grafted nanostructured lipid carriers

Zhao, Chunyan; Fan, Tingting; Yang, Yang; Wu, Meilin; Li, Lian; Zhou, Zhou; Jian, Yanlin; Zhang, Qiang; Huang, Yuan

doi:10.1016/j.ijpharm.2013.04.030

Cited by 27 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These treatment regimes are primarily based on the patternrecognition receptors which are present on the cell surface of macrophages such as the family of scavenger receptors, examples include Fc and complement receptors, mannose receptor Fig. 5 [175][176][177][178][179][180], which are used by macrophages for phagocytosis [181][182][183][184]. In many cases, receptors for amyloid-b peptide [185], high-density lipoprotein [186] and hyaluronic acid [187] were utilized as a candidate for targeted delivery of drug.…”

Section: Nanoparticle Targeting With Macrophages To Control Inflammationmentioning

confidence: 99%

Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases

et al. 2017

View full text Add to dashboard Cite

Degenerative diseases are results of deterioration of cells and tissues with aging either by unhealthy lifestyle or normal senescence. The degenerative disease likely affects central nervous system and cardiovascular system to a great extent. Certain medications and therapies have emerged for the treatment of degenerative diseases, but in most cases bearing with poor solubility, lower bioavailability, drug resistance, and incapability to cross the bloodbrain barrier (BBB). Hence, it has to be overcome with conventional treatment system; in this connection, nanotechnology has gained a great deal of interest in recent years. Moreover, nanotechnology and nanocarrier-based approach drug delivery system could revolutionize the treatment of degenerative diseases by faster absorption of drug, targeted interaction at specific site, and its release in a controlled manner into human body with minimal side effects. The core objective of this review is to customize and formulate therapeutically active molecules with specific site of action and without affecting other organs and tissues to obtain effective result in the improvement of quality of health. In addition, the review provides a concise insight into the recent developments and applications of nanotech and nanocarrier-based drug delivery for the treatment of various degenerative diseases.

show abstract

Section: Nanoparticle Targeting With Macrophages To Control Inflammationmentioning

confidence: 99%

Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases

et al. 2017

View full text Add to dashboard Cite

show abstract

“…NLCs are also prepared by the solvent dispersion method [52,53,54,55,56,57]. This method was used by Emami et al [57].…”

Section: Methods For Preparing Drug Carriersmentioning

confidence: 99%

A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs

Cai

Huang³

et al. 2017

Nanomaterials

188

108

View full text Add to dashboard Cite

Nanostructured lipid carriers (NLCs) are modified solid lipid nanoparticles (SLNs) that retain the characteristics of the SLN, improve drug stability and loading capacity, and prevent drug leakage. Polymer nanoparticles (PNPs) are an important component of drug delivery. These nanoparticles can effectively direct drug delivery to specific targets and improve drug stability and controlled drug release. Lipid–polymer nanoparticles (PLNs), a new type of carrier that combines liposomes and polymers, have been employed in recent years. These nanoparticles possess the complementary advantages of PNPs and liposomes. A PLN is composed of a core–shell structure; the polymer core provides a stable structure, and the phospholipid shell offers good biocompatibility. As such, the two components increase the drug encapsulation efficiency rate, facilitate surface modification, and prevent leakage of water-soluble drugs. Hence, we have reviewed the current state of development for the NLCs’, PNPs’, and PLNs’ structures, preparation, and applications over the past five years, to provide the basis for further study on a controlled release drug delivery system.

show abstract

“…S-NLCs were labeled with coumarin-6 [(3-(2′-benzothiazolyl)-7-diethylaminocoumarin] as previously described [ 48 ]. 1 h after the intravenous (i.v.)…”

Section: Methodsmentioning

confidence: 99%

Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway

et al. 2017

View full text Add to dashboard Cite

BackgroundTreatment of the ischemic stroke has remained a major healthcare challenge. The phenolic compound, sesamol, has shown promising antioxidant and neuroprotective effects, however, fast clearance may negatively affect its efficiency. This, prompted us to incorporate sesamol into the nanostructured lipid carriers (S-NLCs) and evaluate its therapeutic potential in in vitro and in vivo models of ischemic stroke.MethodsS-NLCs formulations were prepared by high-pressure homogenization followed by physicochemical characterization, evaluation of the bioactivity of the optimal formulation in oxygen-glucose deprivation (OGD) and global cerebral ischemia/reperfusion (I/R) injury and implication of phosphatidylinositol 3-kinase (PI3K) pathway in this regard. Two- or three-way ANOVA, Mann-Whitney U test, and Student’s t-test were used for data analysis.ResultsFormation of S-NLCs which exhibited a controlled release profile, was confirmed by scanning electron microscope and differential scanning calorimetry. 1- and 8-h OGD followed by 24 h re-oxygenation significantly reduced PC12 cell viability, increased lactate dehydrogenase activity and the number of condensed nuclei, and induced oxidative stress as revealed by increased malondialdehyde level and decreased glutathione content and superoxide dismutase and catalase activities. Sesamol (80 and 100 μM) reduced the cytotoxicity, oxidative stress, and cellular damage only after 1-h OGD, while, S-NLCs (containing 80 and 100 μM of sesamol) were effective at both time points. Intravenous injections of S-NLCs (20 and 25 mg/kg) into rats markedly attenuated I/R-induced neurobehavioural deficits, cellular damage, and oxidative stress, while, free sesamol failed. Pre-treatment with PI3K inhibitor, LY294002, abolished the protective effects against OGD or I/R.ConclusionsS-NLCs improve the pharmacological profile of sesamol and provide longer lasting protective effects for this phenolic phytochemical. This nanoformulation by activating PI3K pathway may serve as a promising candidate for neuroprotection against the cerebral stroke or other neurodegenerative disorders.Graphical abstractSesamol-loaded NLCs, a promising nanoformulation against the ischemic stroke

show abstract

Preparation, macrophages targeting delivery and anti-inflammatory study of pentapeptide grafted nanostructured lipid carriers

Cited by 27 publications

References 21 publications

Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases

Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases

A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs

Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway

Contact Info

Product

Resources

About